DDInter350 DDInter1376
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Chlorambucil {u} (Compound) treats {v} (Disease) ovarian cancer
Chlorambucil {u} (Compound) binds {v} (Gene) SLCO1A2
Chlorambucil {u} (Compound) upregulates {v} (Gene) DDB2
Chlorambucil {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Chlorambucil {u} (Compound) downregulates {v} (Gene) CENPA
Chlorambucil {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Chlorambucil (Compound) resembles Melphalan (Compound)
Chlorambucil (Compound) treats ovarian cancer (Disease)
Chlorambucil (Compound) binds SLCO1A2 (Gene)
Chlorambucil (Compound) upregulates DDB2 (Gene)
Chlorambucil (Compound) is included by Alkylating Activity (Pharmacologic Class)
Chlorambucil (Compound) downregulates CENPA (Gene)
Chlorambucil (Compound) causes Hyperuricaemia (Side Effect)